International ClinicsMedical News
International Clinics Newsroom · · 1 min read
Daily

EMA recommends daraxonrasib for metastatic pancreatic cancer after a fast-tracked phased review

  • On 15 October 2026 the EMA recommended authorising Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma.
  • Daraxonrasib is an oral RAS inhibitor for adults who have had at least one previous treatment.
  • In a 500-patient study, median survival was 12.4 months with daraxonrasib versus 6.7 months with chemotherapy.
  • The daraxonrasib assessment took less than 150 days thanks to a phased review.
Doctor holding a purple ribbon for pancreatic cancer awareness
Doctor holding a purple ribbon for pancreatic cancer awareness Photo: European Medicines Agency
Published:

The European Medicines Agency's human medicines committee recommended on 15 October 2026 that Rasonque (daraxonrasib) be authorised in the EU. It is an oral treatment for adults with metastatic pancreatic adenocarcinoma who have had at least one previous treatment, a group with few options and a poor outlook, for whom chemotherapy is of limited benefit and highly toxic.

How it works

Daraxonrasib is a RAS inhibitor. RAS proteins control cell growth and survival, and in pancreatic cancer RAS mutations keep them permanently switched on. The drug binds a protein called cyclophilin A, and the resulting complex attaches to RAS and blocks it.

Also read: Daraxonrasib plus chemotherapy shrank tumours in 61% of patients with advanced pancreatic cancer in an early trial

Results

The phase 3 study enrolled 500 patients whose disease had worsened after prior treatment; 92% had a confirmed RAS G12 mutation. Median overall survival was 12.4 months with daraxonrasib versus 6.7 months with chemotherapy, and median progression-free survival was 7.2 versus 3.6 months. The most common side effects were diarrhoea, rash, mouth inflammation, nausea and vomiting.

A faster review

Under its Cancer Medicines Pathfinder project, the EMA assessed the data in phases from early July 2026, cutting the review to under 150 days versus about a year for a standard evaluation. The opinion now goes to the European Commission for a fast-tracked decision.

Sources: European Medicines Agency (EMA), EMA — CHMP meeting highlights, October 2026

This story is relayed from the source named above; responsibility for its content rests with the original source.

FAQ

What is Rasonque (daraxonrasib)?

Rasonque (daraxonrasib) is an oral RAS inhibitor recommended by the EMA for adults with metastatic pancreatic adenocarcinoma after previous treatment.

How much did daraxonrasib extend survival?

In a 500-patient study, median survival was 12.4 months with daraxonrasib versus 6.7 months with chemotherapy.

What are the common side effects of daraxonrasib?

The most common side effects of daraxonrasib are diarrhoea, rash, inflammation of the mouth lining, nausea and vomiting.

Why was the daraxonrasib review faster than usual?

The EMA reviewed daraxonrasib in phases under its Cancer Medicines Pathfinder project, so the assessment took less than 150 days.

Is daraxonrasib already available in Europe?

Not yet. The EMA recommendation for daraxonrasib needs a European Commission decision, after which each country sets price and reimbursement.

How would you rate this story?
3,504
Latest news
A fluoride-free gel that may rebuild tooth enamel, from the University of Nottingham Jackson 5's Marlon Jackson reveals he has lived with prostate cancer for four years Tip of the day: get your flu vaccine early, before winter peaks Every plant-based food in a UK study contained fungal toxins, all within EU guideline levels Tip of the day: spit, don't rinse, after brushing your teeth Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds ISAPS global survey: eyelid surgery leads, breast lift grows fastest and filler declines Hippocrates: "Life is short, and Art long" Born on this day: William Beaumont and the hole in a stomach that rewrote digestion Tip of the day: sleep at least 7 hours a night, on a regular schedule
The latest-news bar is closed. You can bring it back any time with the “Latest news” button in the menu.